Govt's indigenous rotavirus vaccine has side effects: HC told

Image
Press Trust of India New Delhi
Last Updated : Aug 18 2015 | 6:13 PM IST
Clinical trial data of rotavirus 116E vaccine in India have revealed several instances of side effects and these should be disclosed, the Delhi High Court was told today.
The vaccine protects children from rotaviruses, which are the leading cause of severe diarrhoea among infants and young children.
A bench of Chief Justice G Rohini and Justice Jayant Nath was also told that the vaccine was withdrawn from the US due to the number of side effects, but it was being sought to be included in the universal immunisation scheme of India.
The results of the Phase III clinical trials at Vellore had revealed around 581 instances of side effects, the petitioner, a doctor at St Stephen's Hospital here, told the court, which reserved its verdict after also hearing the side of the government.
The petitioner, Dr Jacob Puliyel has moved a petition seeking to restrain the government from moving on to phase IV trials in which over one lakh children would be administered the vaccine.
Puliyel in his plea has also sought directions to the government to provide complete data of the multi-centre clinical trials of the vaccine.
Appearing for Puliyel, advocate Prashant Bhushan argued that trial was conducted between 2011-2013 at various places across the country, but its data was not disclosed.
Bhushan said that as per guidelines of World Health Organisation (WHO), results of clinical trials have to be put in the public domain without delay.
He also said the petitioner was seeking details of the side effects suffered by those who underwent the trial and also details of how many were administered placebos.
Additional Solicitor General (ASG) Sanjay Jain, who appeared for the government, contended that WHO guidelines say the results of the trials are to be disclosed, which was done. The guidelines were not binding and do not say that data has to be disclosed, he added.
Jain also said the vaccine, called Rotovac, was not only the first indigenously developed and manufactured vaccine in the country, but also cheap as one dose would cost only about Rs 60.
The ASG said the rotavirus vaccines currently available in the market cost nearly Rs 1000 per dose.
According to the government rotavirus diarrhoea kills more than one lakh children under the age of five in India every year, a claim which has been opposed by Puliyel.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 18 2015 | 6:13 PM IST

Next Story